In 2019, about 1.5 million coronary stents will be used in China, with a cost of about 15 billion, accounting for one tenth of the total cost of high-value consumables in China. It is expected that soul bargaining or reappearance of similar drugs will be carried out at national level.
The final price of coronary stent products won the bid in the centralized procurement will be less than 2850 yuan. Before, the online prices of corresponding products of enterprises participating in centralized procurement ranged from 7600 yuan to 23000 yuan, and the import price was generally much higher than that of domestic products. Compared with the highest price of 23000 yuan, 2850 yuan decreased by 88%.
Photo source: Photo Gallery
Domestic manufacturers account for more than 60% of the intended purchase volume
Coronary stent is often said to be the heart stent, in the treatment of heart disease, the use rate is very high.
The document stipulates that the scope of products involved in this round of centralized procurement is the listed coronary drug eluting stent system with Chinese medical device registration certificate, which is made of cobalt chromium alloy or platinum chromium alloy, and the drug carrier type is rapamycin and its derivatives. Among the intended products, 27 registered products of 12 enterprises will compete to enter the final list. The total number of intention procurement in the first year is 1074700, which is accumulated by 80% of the total demand submitted by medical institutions in the alliance region. The centralized procurement cycle is 2 years, and the price declaration date of each enterprise is November 5.
Among the 12 enterprises, domestic coronary stent manufacturers include minimally invasive medical (00853, HK), Lepu medical (300003, SZ), lanfan medical (002382, SZ), xinlitai (002294, SZ), etc. Corresponding to the first year, there were 738600 intended purchases, accounting for 68.73% of the total.
At the same time, among the 12 enterprises, minimally invasive medical (36.5%), Boston Medical (11.2%) and Lepu medical (11.2%) had the largest purchase volume in the first year, and domestic enterprises occupied two seats.
Although there are 12 manufacturers with 27 products competing, only the top 10 products will be the first to be shortlisted. The ranking rule is to determine the ranking according to the order of product application quotation from low to high. The lowest quotation is the first, the second lowest is the second, and so on.
However, according to Guosheng Securities Research Report, the online prices of the corresponding products of various enterprises in the first year of intended purchase range from 7600 yuan to 23000 yuan, and the online price of coronary stents of imported enterprises is generally much higher than that of domestic enterprises. At the same time, Societe Generale Securities Research Report predicts that the price competition will be more intense, and the winning price will probably affect the existing ex factory price system of coronary stents.
It is worth noting that October 19 is the first trading day after the above information is released, and the stock prices of coronary stent related enterprises in the secondary market fluctuated significantly. Minimally invasive medical shares fell 11.62% to HK $28.85; Lepu medical shares fell 8.83% to 31.28 yuan; lanfan medical shares fell 3.88% to 24.99 yuan; and xinlitai shares fell 5.29% to 31.70 yuan.
As of October 20, the above four stocks still fell collectively.
On October 19, at the Lepu medical exhibition stand of the 83rd China International Medical Device Expo, Ms. Hu of the companys marketing department told the reporter of the daily economic news (micro signal: nbdnews) that she also noticed that the share prices of related enterprises, including her own company, had fluctuated.
Facing the pressure from foreign investors of centralized mining
From 2009 to 2019, interventional therapy for coronary heart disease has developed rapidly in China. The number of cases per year has increased from 230000 to more than 1 million, with an annual growth rate of 10% - 20%. At present, the number of stents used in each operation is 1.5, which is basically at the same level as foreign countries. It is estimated that about 1.5 million coronary stents will be used in China in 2019, with a cost of about 15 billion, accounting for one tenth of the total cost of high-value consumables in China.
In the first year, the total number of intention to purchase coronary stents was 1074700. The price and use of the selected products in the centralized procurement of coronary stents is expected to be implemented in January 2021, which will affect the market of tens of billion yuan.
Some industry insiders told reporters that for high-value consumables and equipment enterprises, if they fail to win the bid, the pressure will be greater than that of pharmaceutical enterprises, because high-value consumables are basically used in clinical use in large hospitals, and there is no pharmacy market. If it fails to win the bid, only private hospitals will remain in the market outside the medical institutions in the alliance area.
Photo source: Photo Gallery
Ms. Hu of Lepu medical marketing department told reporters that although patients in different regions have different demands for products at various prices, the domestic products of the same kind selected by the company for purchase in the document have already accounted for more than 30% of all domestic products of the same type.
Zhan Jincheng, marketing general manager of aozida medical device service group, introduced to reporters that the clinical application of coronary stent has been more than 30 years. The product involved in this centralized purchase is a standardized product that has been used for many years. At present, the major manufacturers at home and abroad have produced the products, and the technology gap is not big.
But in Zhan Jinchengs view, although the price of imported products was higher before, in fact, because foreign businessmen face the larger market sales in the world, the purchase cost of products is lower than that of domestic enterprises. Therefore, in the same competitive environment, foreign businessmen can get more profits and more competitive than domestic manufacturers costs.
The reporter noted that before the centralized purchase of medicine, some foreign enterprises failed to match the quotations of mainland enterprises, resulting in the final abandonment of the bid. Is it possible for this to happen again in coronary stent harvesting?
Zhan Jincheng believes that even if the price ceiling of 2850 yuan, enterprises still have their own profit space. But the import manufacturers suddenly reduce the price to the same level as the local brands. They dont need to get the maximum quantity. Its good to have a certain market share. Chinas market is also a very important market for foreign investors. If we do not do it at all, the turnover and profits will suddenly decrease a lot, and the pressure on foreign businessmen will be even greater. .
After coronary stenting, it is a consensus that more high-value medical consumables should be included in the national procurement, and some places are exploring. For example, the second batch of high-value medical consumables in Anhui Province, such as orthopedic joint products and cardiac pacemakers, were successfully purchased, with an average decrease of 81.97% for 240 orthopedic joint products and 46.75% for 82 cardiac pacemakers. Reporter, Hua angjin, editor, Chen Junjie, Lu Xiangyong, Du Bo proofread, he Xiaotaos extended reading, and Goldman Sachs has recognized its failure again! Will pay more than $2 billion to the U.S. Department of justice to absolve Zhao Benshan, who once spoke for Huoxiang Zhengqi king for 10 years, losing 2 billion or changing ownership_ NF4368
After coronary stenting, it is a consensus that more high-value medical consumables should be included in the national procurement, and some places are exploring. For example, the second batch of high-value medical consumables in Anhui Province, such as orthopedic joint products and cardiac pacemakers, were successfully purchased, with an average decrease of 81.97% for 240 orthopedic joint products and 46.75% for 82 cardiac pacemakers.